Quercetin

MDA awarded 21 grants totaling over $5M for neuromuscular disease research, including 14 research grants and 7 development awards. Focus areas include ALS, DMD, SMA, FSHD, and LGMD, with collaborations like AFM-Téléthon and Coalition to Cure Calpain 3. Grants aim to uncover new therapeutic targets and treatments.

Risperidone, a second-generation antipsychotic, treats schizophrenia, bipolar disorder, and autism-related hyperactivity. It inhibits D2 dopamine and 5-HT2A serotonin receptors, reducing psychotic symptoms. Risperidone nano/microcarriers enhance bioavailability, reduce side effects, and improve patient compliance. Formulation strategies include liposomes, nanoparticles, nanoemulsions, and niosomes, aiming to improve solubility, stability, and targeted delivery. Toxicological studies highlight neurological and immunosuppressive side effects. Clinical trials show efficacy in psychosis management, and patents focus on innovative formulations. Future research aims to optimize nano/microcarrier systems for better drug delivery.

References discuss periodontitis, RANKL/OPG regulation by Porphyromonas gingivalis, silibinin's anti-inflammatory effects, oxidative injury in periodontal diseases, mesenchymal stem cell therapy, 2D/3D culture impacts, organ-on-a-chip applications, periodontal tissue regeneration, local adjuncts in periodontal therapy, icariin's benefits, microfluidic platforms, 3D cell printing, hMSC cocultures, osteogenesis regulation, quercetin and catechin effects, nanoemulgel development, and Wnt/β-catenin signaling.

Articles discuss AML diagnosis, management, and treatment, including venetoclax efficacy, genomic landscape in leukemia, and quercetin's anticancer effects.